Yunkang Group Limited

HKSE 2325.HK

Yunkang Group Limited Gross Profit Margin for the year ending December 31, 2023: 36.54%

Yunkang Group Limited Gross Profit Margin is 36.54% for the year ending December 31, 2023, a 8.84% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Yunkang Group Limited Gross Profit Margin for the year ending December 31, 2022 was 33.58%, a -35.61% change year over year.
  • Yunkang Group Limited Gross Profit Margin for the year ending December 31, 2021 was 52.15%, a -3.12% change year over year.
  • Yunkang Group Limited Gross Profit Margin for the year ending December 31, 2020 was 53.83%, a 25.96% change year over year.
  • Yunkang Group Limited Gross Profit Margin for the year ending December 31, 2019 was 42.74%, a 10.59% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
SV Wall Street
HKSE: 2325.HK

Yunkang Group Limited

CEO Mr. Yong Zhang
IPO Date May 18, 2022
Location China
Headquarters No. 9 Yayingshi Road
Employees 1,459
Sector Healthcare
Industries
Biotechnology Dental Care Medical Instruments Pharmaceuticals Telehealth Vaccines
Description

Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction and screening tests; and routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. In addition, the company offers diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; healthcare technology development; and project investment. It provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.

StockViz Staff

February 8, 2025

Any question? Send us an email